Printer Friendly

Xeotron is Granted Patent by US Patent Office.

Business Editors



Xeotron Corporation announced today that the United States Patent and Trademark Office has granted U.S. patent #6,426,184 for its technology invention "Method and apparatus for chemical and biochemical reactions using photo-generated reagents." This patent covers a new method and an integrated system of equipment necessary for the synthesis of chemical microarrays in situ. This system enables the parallel production of arrays containing oligonucleotides, both DNA and RNA, as well as peptides and carbohydrates. The patent will enable Xeotron to continue to produce highly uniform microarrays on a substrate using conventional monomers with reaction times comparable to conventional oligonucleotide synthesis, reducing the overall cost of microarray production.

"This invention makes Xeotron's platform truly unique. Proven, conventional synthesis chemistries are now available in a massively parallel format. It opens the door to a broad range of applications," said Tim McGrath, CEO of Xeotron.

"The issuance of this patent is timely for commercializing Xeotron's products. It significantly bolsters our intellectual property position," commented David Sun, Xeotron's vice president of Business Development and Marketing.

Xeotron has developed microfluidic bioarrays, or XeoChips, for gene expression studies to meet the specifications of individual researchers. Unlike other commercially available chips, XeoChips enable very rapid discovery cycles because production time is greatly reduced. The XeoChips' major advantages in quality, cost, flexibility and quick turn-around are the result of Xeotron's novel and proprietary technology platform combining the photo-generated reagent (PGR) photochemistry, digital photonics and microfluidics.

About Xeotron Corporation

Xeotron produces microarrays using proprietary platform technology that combines digital photonics, microfluidics and photochemistry. This technology allows the production of high quality custom bioarrays with quick turn-around, at an affordable price. Based on this technology, discovery cycles are more rapid because iterative rounds of probes can be quickly synthesized within days, instead of months. The XeoChips can be used with existing equipment, dramatically lowering entry costs and allowing greater access to more researchers.
COPYRIGHT 2002 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Dec 10, 2002
Previous Article:Lightolier Controls' Compose PLC Receives High-Impact Product Of The Year Award; Compose PLC Recognized For Positive Impact On Home Automation...
Next Article:Ovum Research Commends iPIN Technology in Latest Report On Mobile Payment Providers.

Related Articles
Patent requirements. (Technote - Software Intelligence).
Process protection: armed with a boost from the federal courts, insurers are increasingly turning to patents to prevent competitors from copying...
Legacy Electronics gets 3-D memory module patent.
Kadant granted patent on bi-metal blade technology.
Government decides: patents for internet trading and computer software.
War on bogus internet patents.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters